How has Tarsus Pharmaceuticals, Inc.'s stock issuance proceeds changed year-over-year?

Tarsus Pharmaceuticals, Inc.'s stock issuance proceeds decreased by 100.0% year-over-year, from $135.13M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Tarsus Pharmaceuticals, Inc. TARS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Bausch + LombBLCO

$2M—

Ocular TherapeutixOCUL

$294K-93.0%

Kodiak Sciences IncKOD

$922K+644%

Regeneron PharmaceuticalsREGN

$163.1M+169%

Warby ParkerWRBY

$0-100%

GlaukosGKOS

$19.33M+374%

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.85B+41.1%

Enterprise value$2.83B+47.8%

P/S5.3×-3.3×

Profitability

See full

Gross margin42.7%—

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s stock issuance proceeds?: Tarsus Pharmaceuticals, Inc. (TARS) reported stock issuance proceeds of $0 in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s stock issuance proceeds changed year-over-year?: Tarsus Pharmaceuticals, Inc.'s stock issuance proceeds decreased by 100.0% year-over-year, from $135.13M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.